Shares of Aurobindo Pharma closed the day with 4.5 per cent gains after the company received final approval from the USFDA to manufacture and market Sevelamer Carbonate tablets in the American market.
The tablets are indicated for control of serum phosphorus in patients with chronic kidney disease on dialysis.
The scrip ended at Rs 766.65, up 4.48 per cent on BSE. Intra-day, it gained 8.27 per cent to Rs 794.50.
At NSE, shares of the company rose by 4.29 per cent to end at Rs 765.85.
The company's market valuation went up by Rs 1,927.67 crore to Rs 44,916.67 crore.
In terms of volume, 7.09 lakh shares of the company were traded on BSE and over one crore shares changed hands at NSE during the day.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg," Aurobindo Pharma said in a BSE filing today.
Disclaimer: No Business Standard Journalist was involved in creation of this content
